Multinational nephrology firm Fresenius Medical Care eventually wants as many as 200,000 samples in its registry and aims to sequence 20,000 patients this year.
By uncovering genetic factors behind blood and urine biomarkers, researchers came up with polygenic scores related to biomarker status and related disease risk.
Bio-Techne said that it is collaborating with Regulus to develop assays to support the assessment of levels of polycystin 1 and polycystin 2 in clinical trial testing.
The firm recently described circumstances in which the fraction of host or donor DNA could be altered, and plans new approaches to data interpretation.
In PNAS this week: genetic and epigenetic variation in individuals with diabetic kidney disease, spontaneous genetic alterations in Saccharomyces cerevisiae, and more.
The firms will initially use RenalytixAI's KidneyIntelX platform to help improve outcomes for patients with chronic kidney disease and its complications.
RenalytixAI's flagship product is KidneyIntelX, which applies artificial intelligence to patient data to aid in the treatment of progressive kidney disease.
KidneyIntelX can be used to report risk assessment results for fast-progressing kidney disease and future kidney failure for patients with chronic kidney disease.
The firm believes the multi-part stratification project will help further commercialization of its KidneyIntelX blood-based assay for acute and chronic kidney disease.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
